FDA Counters Pfizer’s CEO on Second Paxlovid Course After Rebound
One day after Pfizer CEO Albert Bourla said physicians could prescribe a second course of the company’s oral COVID-19 treatment Paxlovid to patients who suffer a rebound, the FDA refuted…